A huge number of therapeutic studies has been published in rheumatology and clinical immunology. This number grows substantially by the year. As such, it becomes increasingly difficult to keep track of this multitude of studies and the ensuing therapeutic trends. Further to this, a particular study can be referred to in a variety of ways, either as a shortened version of the title or an acronym, adding to the confusion. The book Clinical Trials in Rheumatology, Second Edition, provides an ...

A huge number of therapeutic studies has been published in rheumatology and clinical immunology. This number grows substantially by the year. As such, it becomes increasingly difficult to keep track of this multitude of studies and the ensuing therapeutic trends. Further to this, a particular study can be referred to in a variety of ways, either as a shortened version of the title or an acronym, adding to the confusion. The book Clinical Trials in Rheumatology provides a summary of the imp...

For the world's largest prescription drug manufacturers, the last few years have been a harrowing time. Recently, Pfizer's Lipitor, GlaxoSmithKline's Advair, AstraZeneca's Seroquel, and Sanofi-Aventis and Bristol-Myers Squibb's Plavix all came off patent in the crucial U.S. market. This so-called "patent cliff" meant hundreds of billions of dollars in lost revenue and has pharmaceutical developers scrambling to create new drugs and litigating to extend current patent protections. Having sp...

Rheumatology: Clinical Scenarios is a case-based learning tool for trainees in rheumatology. Professor Efim Benenson presents 73 clinical scenarios and 156 clinical images for the student of rheumatology to diagnose, whilst his expert commentary is provided in a separate section. As a further diagnostic aid, two ‘Rheumatology Trees’ are provided which summarize in turn the articular and musculoskeletal disorders, as well as the connective tissue disorders and vasculitides.Professor...

The antiphospholipid syndrome (Hughes syndrome) is now over a quarter of a century old. Although most of the major clinical features were described in the original papers between 1983 and 1985, the ensuing 25 years have seen a filling out of the clinical detail and recognition that the syndrome is of major medical importance. More significantly, much has been learnt of the prevalence and epidemiology of the syndrome as well as the biology of the thrombotic process so central to the conditi...

Rheumatologic diseases are highly associated with clinical symptoms of the skin, nails, and mucosal membranes. This book provides the practicing rheumatologist with a rapid, easy to consult reference to help interpret the nature of these cutaneous lesions and then quickly decide upon the appropriate follow-up tests. Utilizing an abundance of informative photographs, it contains all of the essential information needed for early diagnosis and treatment. This comprehensive guide properly orie...

Rheumatology: Symptoms and Syndromes organizes the rheumatic diseases in the form of syndromes as stable combinations of symptoms, and links these to morphological manifestations. This presentation of the rheumatic diseases provides a pedagogical framework for differential diagnosis in rheumatology. To further aid the teacher and student, Professor Efim Benenson provides algorithms of clinical reasoning based on morphology and pathophysiology. Professor Benenson’s practice-oriented, didact...

Behçet's syndrome can reasonably be considered a unique entity among diseases of the immune system for several reasons: It has specific features and, uniquely among the immune system pathologies, represents a link between autoimmune diseases, systemic vasculitis, and autoinflammatory diseases. In addition, it is of interest to a variety of specialists, including immunologists, rheumatologists, dermatologists, and ophthalmologists, and requires a complex multidisciplinary approach. Many asp...

Introduction by Bernhard Meier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xi Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xxxiii Theoretical ...

Arachidonic acid (AA) and other 20 or 22-carbon polyunsaturated fatty acids (PUFAs) are precursors of lipid mediators of inflammation known as eicosanoids. These mediators are critical in disease processes and in regulating normal cell function. Remodeling is important in maintaining homeostasis and in regulating cell function by dictating how PUFAs are converted to lipid mediators of inflammation. Thus, PUFA remodeling is a critical process in the biosynthesis of a multitude of mediators,...

This book is an essential guide to the medical treatment of the cardiac patient and presents core principles of cardiovascular therapeutics as well as drug recommendations. Major classes of drugs are featured, including beta-blockers, ACE inhibitors, calcium antagonists, diuretics, and antiplatelet agents and unique insights into the controversies surrounding the use of specific drugs are explored, with answers given to the question: do beta blockers and diuretics really cause diabetes? Pr...

This book provides a detailed overview of B-cell directed therapies in patients with rheumatic and systemic autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, ANCA-associated vasculitis and cryoglobulinemia. Organ-specific autoimmune diseases are discussed with respect to the use of B-cell directed therapies in neurological autoimmune diseases and autoimmune cytopenias. Situations in which B-cell targeted therapy may be indicated are identi...